Barclays’s DarioHealth DRIO Stock Holding History

Barclays’s Portfolio DRIO Stock Details DRIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2	Closed	-$21	–	5337
2025 Q1	$21	Buy	+2	New	+$28	﹤0.01%	5169
2022 Q2	–	Sell	-109	Closed	-$13K	–	5079
2022 Q1	$13K	Buy	+109	New	+$18K	﹤0.01%	4547

Other funds holding DRIO

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

AWAM

Appian Way Asset Management New York $558M AUM 1.95% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

YDMI

Y.D. More Investments Ramat Gan, Israel $2.55B AUM 104.35% 1-Year Est. Return

Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

DIM

DLK Investment Management Solana Beach, California $235M AUM 12.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Barclays's DRIO Position: Q2 2025 in Review

Barclays sold out of DarioHealth (DRIO) in Q2 2025, closing a stake of 2 shares — an estimated $21 sold.

Barclays first reported a position in DRIO in Q1 2022 and held it in 2 quarters. The position peaked at $13K in Q1 2022. 39 funds tracked by Wall St. Rank hold DRIO as of Q2 2025.

Barclays reported no remaining DarioHealth position as of Q2 2025 after selling out during the quarter.
Barclays sold 2 DarioHealth shares in Q2 2025, an estimated $21.
Barclays first reported a position in DarioHealth in Q1 2022 and held it in 2 quarters.
Barclays's DarioHealth position peaked at $13K in Q1 2022.
39 funds tracked by Wall St. Rank held DarioHealth as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.